Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy

NCT01811485 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: LMF237 50/250 mg
DRUG: LMF237 50/500 mg
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals